Home > Subject >


Addressing Residual Cardiovascular Risk

Charles A. Reasner, M.D.
Volume 29, Number 2, pages 30-31

Advanced Lipid Testing

Michael Cobble, M.D., A.A.F.P., F.N.L.A., and Jill Sellers, B.S.Pharm., Pharm.D.
Volume 29, Number 3, pages 22-26

AIM-HIGH Misses Its Target

Charles A. Reasner, M.D.
Volume 30, Number 3, pages 29-30

Clinical Controversies in Diabetes

Daniel L. Lorber, M.D.
Volume 21, Number 3, pages 22-32

Commentary: Application of the AACE 2017 Lipid Guidelines to Diabetes

Kathleen Wyne, M.D., Ph.D.
Volume 36, Number 3, pages 7-9

Lipid Changes Associated with Diabetes Therapy

John B. Buse, M.D., Ph.D., C.D.E.
Volume 22, Number 1, pages 24-29

Managing Diabetic Dyslipidemia

Peter P. Toth, M.D., Ph.D., F.A.A.F.P., F.N.L.A., F.C.C.P., F.A.H.A., F.A.C.C.
Volume 29, Number 1, pages 18-25

Rational Therapy of Dyslipidemia in Patients With Type 2 Diabetes

Charles A. Reasner, M.D.
Volume 26, Number 4, pages 28-33

Treatment of Low HDL Cholesterol Level—Too Little, Too Late

Charles A. Reasner, M.D.
Volume 28, Number 1, pages 29-31

Understanding the Links Between Insulin Resistance, Diabetes, and Cardiovascular Risk

Melvin R. Hayden, M.D., and Brian S. McGowan, Ph.D.
Volume 24, Number 2, pages 6-14

Use of Bile Acid Sequestrants to Treat Type 2 Diabetes

Charles A. Reasner, M.D.
Volume 28, Number 2, pages 6-15

Vitamin D Deficiency and Diabetes

David S.H. Bell, M.B., F.A.C.E.
Volume 30, Number 4, pages 6-21